USP Negative Ephedra Monograph To Follow FDA Final Action
This article was originally published in The Tan Sheet
Executive Summary
The United States Pharmacopeia plans to create a negative monograph for ephedra following FDA action on the dietary supplement ingredient, CEO Jerome Halperin said at a meeting of the USP Ad Hoc Panel on Botanicals in Rockville, Md. Nov. 8.
You may also be interested in...
Chaparral AER Data Resembles Kava Reports, CRN’s Cardellina Says
Adverse event reports on chaparral have certain parallels with those that have been filed for kava, according to Council for Responsible Nutrition VP-Botanical Science & Regulatory Affairs John Cardellina, PhD
Chaparral AER Data Resembles Kava Reports, CRN’s Cardellina Says
Adverse event reports on chaparral have certain parallels with those that have been filed for kava, according to Council for Responsible Nutrition VP-Botanical Science & Regulatory Affairs John Cardellina, PhD
Chaparral AER Data Resembles Kava Reports, CRN’s Cardellina Says
Adverse event reports on chaparral have certain parallels with those that have been filed for kava, according to Council for Responsible Nutrition VP-Botanical Science & Regulatory Affairs John Cardellina, PhD